Sunshine Lake Pharma Co., Ltd.
6887.HK
Hong Kong Stock Exchange34.70
HKD
+0.06
- -
ISIN
CNE1000070M8
Return %
Stock
S&P500
1Y
-42.07
24.99
3Y
-42.07
70.19
5Y
-42.07
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Wen Jia Li
- Full Time Employees
- 6,353
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- HEC Scientific Park Dongguan People's Republic of China 523850
- IPO Date
- Aug 7, 2025
- Website
- hecpharm.com
- Similar Companies
- Business
- Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for infectious diseases, chronic diseases, and oncology; it also participates in wholesale, retail, import, and export of drugs. The company operates via a vertically integrated model encompassing R&D, production, and commercialization of medicines, with a portfolio that includes anti-infectives (Kewei/oseltamivir phosphate, emitasvir phosphate Dongweien, plus associated generics) and therapies for chronic diseases (multiple insulin products and other chronic-disease generics). Sunshine Lake Pharma is publicly listed on the Hong Kong Stock Exchange under ticker 6887.HK, is headquartered in China, and maintains operations across manufacturing sites, a robust R&D platform, and a broad sales network, with a focus on innovative drugs, modified new drugs, generics, and biosimilars. Founding year and headquarters Sunshine Lake Pharma is a Chinese pharmaceutical company founded in 2001 (per various public company profiles and listing documents) and maintains its headquarters in China, with primary manufacturing and R&D facilities used to develop and commercialize its drug portfolio. Products and services (core offerings) - Anti-infective products: Kewei (oseltamivir phosphate) and Dongweien (emitasvir phosphate) as top-selling or major anti-infectives; a portfolio of additional anti-infective generics including macrolides, fluoroquinolones, and related agents; active pharmaceutical ingredients (APIs) and related formulation services. - Chronic disease therapies: Insulin family products (including human insulin injections, mixed protamine human insulin injections such as 30R, insulin glargine, insulin aspart, and insulin aspart 30); other major chronic-disease treatment generics. - Biosimilars and innovative drugs: In-house development pipeline spanning Class I innovative drugs and biosimilars; collaboration and licensing activities to advance drug candidates toward commercialization. - Drug development and collaboration services: In-house R&D with a focus on infectious diseases, chronic diseases, and oncology; licensing and collaboration agreements to co-develop or commercialize products with strategic partners. Geographic and market footprint - Geographic operations primarily based in China with regulatory filings and commercialization efforts anchored in the Chinese market; distribution through domestic networks and partnerships to support wholesale and retail channels; potential licensing and collaboration arrangements aimed at expanding international reach through partners and strategic alliances. Recent major changes and strategic activity (within the last 1–2 years) - Strategic collaborations and licensing: Engages in licensing and commercialization agreements (including collaborations with external groups) to advance drug candidates and expand its product portfolio; ongoing partnerships to accelerate development and market entry of key products. - Product-launch activity and pipeline advancement: Continues to advance insulin and anti-infective products through development and potential market introduction; in-house development of Class I innovative drugs and biosimilars to broaden therapeutic reach. - Corporate and organizational updates: Ongoing expansion of R&D capabilities and production capacity to support a growing pipeline and escalation of manufacturing scale; potential reorganizations or strategic realignments to integrate in-house R&D with commercial operations. - Acquisitions and funding: Public disclosures indicate active participation in strategic deals and potential funding rounds related to pipeline advancement and business expansion; exact terms and partners vary by announcement date. Industry positioning and subsidiaries - Sector: Healthcare, with a focus on drug manufacturing, generic and innovative therapeutics, and biosimilars. - Substructure: Integrated R&D platform, manufacturing facilities, and commercialization networks; potential subsidiary and affiliate network for regional and product-specific activities; linked to parent or sister entities through licensing and collaboration agreements. Notes - Information reflects Sunshine Lake Pharma Co., Ltd. as listed (6887.HK) with a portfolio centered on infectious diseases and chronic diseases, including insulin products and anti-infectives, complemented by an active in-house R&D program and external collaborations to extend its product reach and pipeline.